Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
- PMID: 25769911
- DOI: 10.1016/j.jaci.2015.01.018
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
Abstract
Background: IL-23 is associated with plaque psoriasis susceptibility and pathogenesis. BI 655066 is a fully human IgG1 mAb specific for the IL-23 p19 subunit.
Objective: This first-in-human proof-of-concept study evaluated the clinical and biological effects of BI 655066 in patients with moderate-to-severe plaque psoriasis.
Methods: We performed a single-rising-dose, multicenter, randomized, double-blind, placebo-controlled, within-dose cohort phase I trial. Patients received 0.01, 0.05, 0.25, 1, 3, or 5 mg/kg BI 655066 intravenously, 0.25 or 1 mg/kg BI 655066 subcutaneously, or matched placebo. The primary objective was safety evaluation.
Results: Thirty-nine patients received single-dose BI 655066 intravenously (n = 18) or subcutaneously (n = 13) or placebo (n = 8). Adverse events were reported with similar frequency in the BI 655066 and placebo groups. Four serious adverse events (not considered treatment related) were reported among BI 655066-treated patients. BI 655066 was associated with clinical improvement from week 2 and maintained for up to 66 weeks after treatment. At week 12, 75%, 90%, and 100% decreases in the Psoriasis Area and Severity Index were achieved by 87%, 58%, and 16% of BI 655066-treated patients (any dose), respectively, versus none receiving placebo. BI 655066 treatment resulted in reduced expression of lesional skin genes associated with IL-23/IL-17 signaling pathways and normalization of psoriatic lesion gene expression profiles to a profile approaching that of nonlesional skin. Significant correlation between treatment-associated molecular changes and psoriasis area and severity index improvement was observed (r = 0.73, P = 2 × 10(-6)).
Conclusions: BI 655066 was well tolerated and associated with rapid, substantial, and durable clinical improvement in patients with moderate-to-severe psoriasis, supporting a central role for IL-23 in psoriasis pathogenesis.
Keywords: IL-23A; biomarkers; mAb; pharmacokinetics; psoriasis; randomized; single dose.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025. J Allergy Clin Immunol. 2014. PMID: 24679469 Clinical Trial.
-
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.Curr Med Res Opin. 2007 May;23(5):1081-92. doi: 10.1185/030079907x182112. Curr Med Res Opin. 2007. PMID: 17519075 Clinical Trial.
-
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. Lancet. 2018. PMID: 30097359 Clinical Trial.
-
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28. J Dermatolog Treat. 2018. PMID: 29532693 Review.
-
Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.Immunotherapy. 2015;7(4):323-33. doi: 10.2217/imt.14.113. Immunotherapy. 2015. PMID: 25917624 Review.
Cited by
-
ABD-Derived Protein Blockers of Human IL-17 Receptor A as Non-IgG Alternatives for Modulation of IL-17-Dependent Pro-Inflammatory Axis.Int J Mol Sci. 2018 Oct 9;19(10):3089. doi: 10.3390/ijms19103089. Int J Mol Sci. 2018. PMID: 30304852 Free PMC article.
-
Interleukin 6 regulates psoriasiform inflammation-associated thrombosis.JCI Insight. 2016 Dec 8;1(20):e89384. doi: 10.1172/jci.insight.89384. JCI Insight. 2016. PMID: 27942589 Free PMC article.
-
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody.MAbs. 2015;7(4):778-91. doi: 10.1080/19420862.2015.1032491. Epub 2015 Apr 23. MAbs. 2015. PMID: 25905918 Free PMC article.
-
Crosstalk: keratinocytes and immune cells in psoriasis.Front Immunol. 2023 Nov 9;14:1286344. doi: 10.3389/fimmu.2023.1286344. eCollection 2023. Front Immunol. 2023. PMID: 38022549 Free PMC article. Review.
-
Autoreactive T-Lymphocytes in Inflammatory Skin Diseases.Front Immunol. 2019 May 29;10:1198. doi: 10.3389/fimmu.2019.01198. eCollection 2019. Front Immunol. 2019. PMID: 31191553 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical